StemCell Therapy

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Neuropathy Pain Treatment Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Neuropathy Pain Treatment Market Overview

The Neuropathy Pain Treatment Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Neuropathy Pain Treatment market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Neuropathy Pain Treatment Market: Competitive Landscape

The Neuropathy Pain Treatment Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Neuropathy Pain Treatment Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Neuropathy Pain Treatment Market Segment by Type:

Neuropathy Pain Treatment Market Segment by Application:

Neuropathy Pain Treatment Market Regional overview:

In the report, experts analyze and forecast the Neuropathy Pain Treatment market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Neuropathy Pain Treatment Market Report:

Outlook analysis of the Neuropathy Pain Treatment market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Neuropathy Pain Treatment market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Read the original post:
Neuropathy Pain Treatment Market Size, Share, Statistics, Trends, Demand and Revenue, Forecast To 2027 - The Haitian-Caribbean News Network

Global Ischemic Optic Neuropathy Treatment Market: Overview

Technological progress made in the treatment of ischemic optic neuropathy coupled with the availability of alternative drugs is expected to boost the growth of the global ischemic optic neuropathy treatment market over the period of analysis, from 2020 to 2030. Ischemic optic neuropathies(IONs) are one of the major reasons for seriously impaired vision or blindness usually amongst the elderly and middle-aged people. However, the disease can affect anyone and no human age is immune to it. Increased prevalence of the disease is anticipated to propel expansion of the global ischemic optic neuropathy treatment market in the years to come.

Ischemic optic neuropathies (IONs) come in two types, namely posterior ischemic optic neuropathy (PION) and anterior ischemic optic neuropathy (AION). Inflammation of the arteries that supply blood to the optic nerve causes anterior ischemic optic neuropathy and reasons other than inflammation cause non-anterior ischemic optic neuropathy. However, anterior ischemic optic neuropathy is more commonly found in people than posterior ischemic optic neuropathy. Immediate treatment is needed in case of anterior ischemic optic neuropathy to prevent loss of vision in the affected eye as it also causes damage in the other eye in a span of just 5 to 10 days.

Request Brochure for Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78358

Hypercholesterolemia, diabetes, and hypertension are some of the causes of the disease. In addition, other medical conditions such as failure of autoregulation, severe anemia, vasospasm, nocturnal hypotension, sleep apnea, and hypoperfusion are likely to cause ischemic optic neuropathies.

Disease type, treatment type, end user, and region are the four important parameters based on which the global ischemic optic neuropathy treatment market has been classified. The thorough evaluation of the market comes with the objective of providing stakeholders with a detailed and clear analysis of the global ischemic optic neuropathy treatment market.

Request for Analysis of COVID19 Impact on Ischemic Optic Neuropathy Treatment Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78358

Global Ischemic Optic Neuropathy Treatment Market: Notable Developments

One of the significant developments that give a quick view of the dynamics pertaining to the global ischemic optic neuropathy treatment market is mentioned as below:

Some of the prominent organizations in the global Ischemic optic neuropathy treatment market comprise the below-mentioned:

Pre book Ischemic Optic Neuropathy Treatment Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=78358&ltype=S

Global Ischemic Optic Neuropathy Treatment Market: Key Trends

The global ischemic optic neuropathy treatment market is characterized by the presence of the following restraints, drivers, and opportunities.

Increased Demand from Various End Use Sectors to Fuel Market Growth

The development of the global ischemic optic neuropathy treatment market is anticipated to register high growth rate over the tenure of assessment. The increased use of intravitreal implants for treating ophthalmology diseases is expected to open new avenues of growth for the global ischemic optic neuropathy treatment market over the forecast period, from 2020 to 2030. Many of the leading drug manufacturing and pharmaceutical companies from the developed countries are making high investment in the research and development activities so to develop better and advanced solutions and reduce the burden of vision and eye-related diseases. Increased spending in infrastructure and new, advanced technologies in ophthalmology therapeutics are likely to account for a larger share of the market in the years to come.

For patients suffering from ischemic optic neuropathy, corticosteroid is considered as the first choice of therapy, particularly in countries like Russia, France, Germany, and the US. However, several patients have developed resistance to anti-VEGF, which is likely to boost growth of the global ischemic optic neuropathy treatment market over the period of analysis, from 2020 to 2030.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read more here:
Ischemic Optic Neuropathy Treatment Market set to witness surge in demand over the forecast period 2020-2030 - Murphy's Hockey Law

Staff Reports Published 6:41 p.m. ChT Nov. 30, 2020

Mark Torre Jr. and his attorney Jay Arriola react after a jury found Torre not guilty of all charges on Nov. 23, 2020. Pacific Daily News

A man sentenced to prison for distributing methamphetamine will be released after the court found substantial evidence of physical ailments, including contracting the coronavirus twice.

On July 25, 2016, the court sentenced Franklin John Salas to nine years imprisonment.Salas has served 60% of his prison sentence, and at sentencing was assigned the lowest criminal history category because his crime was nonviolent.

According to the District Court of Guam, Salas suffers from Type II diabetes, diabetic neuropathy, eye cataracts, hypertension, pressure ulcers on his buttocks and foot, chronic kidney disease, and obesity.

In 2016, he suffered a hip fracture and had surgery. In 2017, he fractured his right knee, which according to court documents, doctors at the prison have been unable to treat.

"Walking on his own is extremely painful, and so (he) has been confined to a wheelchair for the last four years," court documents read. Since the start of his incarceration, Salas gained 50 pounds.

More: GPD investigating skull found on shoreline in Hagta

During the coronavirus outbreak, Salas was infected with the coronavirus twice. He has since suffered chills, body aches, loss of appetite, loss of taste, and fatigue, according to court documents.

"He has difficulty in wheeling himself around because of this fatigue, and thus must always have a fellow prisoner assigned to help push his wheelchair," court documents state. Salas also lives in the same room as dozens of other inmates, and they share three bathrooms and one urinal.

More: Don't click that link: Free chicken announcement on WhatsApp is a hoax, KFC Guam says

The court has reduced his sentence to the time he served, and will release him, subject to the surrender of his passport and regular monitoring.

Salas still faces three years of supervised release, during which he will have to comply with conditions already imposed on him.

Read or Share this story: https://www.guampdn.com/story/news/local/2020/11/30/man-jailed-distributing-methamphetamine-released-after-proof-physical-ailments/6461376002/

Continue reading here:
Man jailed for distributing methamphetamine to be released after proof of physical ailments - Pacific Daily News

MediciNovaannounced today that it received positive Optical Coherence Tomography (OCT) results from its SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis (MS) subjects. The results were published in the Multiple Sclerosis Journal.

A total of 28 sites participated in the trial, with 22 sites using Zeiss Cirrus OCT and six sites utilizing Heidelberg Spectralis OCT. In all, 183 subjects were imaged with Cirrus, while 61 were imaged with Spectralis. All of the OCT measures showed less loss of retinal tissue in subjects who received MN-166, compared to a placebo.

Change in peripapillary retinal nerve fiber layer thickness was +0.0424 uM/year for MN166 (ibudilast) versus 0.2630 uM/year for the placebo. Macular volume change was 0.00503 mm3/year for MN-166 compared to 0.03659 mm3/year for placebo in the Spectralis arm. In the Cirrus cohort, macular volume change was 0.00040 mm3/year for MN-166 (ibudilast) compared to 0.02083 mm3/year for the placebo.

We are very pleased that the positive OCT data has been published, said Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc. This data demonstrates that MN-166 can reduce retinal thinning in progressive MS patients and is further evidence of its neuroprotective effect as retinal thinning is associated with brain volume loss and other measures of MS progression.

However, this is not the only condition that MN-166 is being investigated for, according to news published by the company back in September. MediciNova announced earlier this fall that it had received positive clinical findings for MN-166 for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). The results were published in the journal Cancer Chemotherapy and Pharmacology.

Dr. Janette Vardy, Professor of Cancer Medicine, University of Sydney Concord Cancer Centre in Australia, helped lead the research with MediciNova. The authors of the report found that the co-administration of MN-166 with oxaliplatin appeared to result in the improvement or stabilization of oxaliplatin-induced neurotoxicity.

The open-label, sequential crossover study was conducted to determine if MN-166 could reduce acute peripheral neuropathy symptoms in subjects with cancer specifically metastatic upper gastrointestinal or colorectal cancer. A total of 14 patients completed two cycles of oxaliplatin-containing chemotherapy, one cycle with conventional chemotherapy, and one cycle of chemotherapy with concurrent MN-166 treatment.

The subjects underwent a series of assessments for neurotoxicity on Day 3 of each cycle. Once they completed a cycle, they were assessed based on scales including the Oxaliplatin-Specific Neurotoxicity Scale (OSNS), the Total Neuropathy Score Clinical (TNSc), the Functional Assessment of Cancer Therapy/Gynaecologic Oncology GroupNeurotoxicity (FACT/GOG-Ntx13), and the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) neuropathy subscale. Across all neurotoxicity measures, most respondents experienced either an improvement or no worsening of neurotoxicity with MN-166 treatment.

We are very pleased to report positive results from this study, Iwaki said at the time of the results publication. Acute neurotoxicity, which predicts chronic CIPN, usually recurs with oxaliplatin chemotherapy and in most cases, patients experience worsening of neurotoxicity symptoms with continued chemotherapy. What makes this remarkable is that half of participants reported improved symptoms in the acute period and showed improved neurological parameters on clinical assessment with ibudilast treatment.

MN-166 is a first-in-class, orally bioavailable, small molecule macrophage migration inhibitory factor inhibitor. It is also a phosphodiesterase (PDE) -4 and -10 inhibitor that suppresses pro-inflammatory cytokines. MediciNova is developing MN-166 for a wide range of conditions, including progressive MS, ALS and other neurological conditions.

Most read today on BioSpace:

Originally posted here:
MediciNova's Ibudilast Reduces Retinal Thinning in MS Trial Subjects - BioSpace

The global Diabetic Neuropathy Drugs market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and future status of the global Diabetic Neuropathy Drugs market. The research study comes out as a compilation of useful guidelines for players to secure a position of strength in the global Diabetic Neuropathy Drugs market. The authors of the report profile leading companies of the global Diabetic Neuropathy Drugs market, such as Pfizer, Novartis, Johnson & Johnson, Eli Lilly, GlaxoSmithKline, Boehringer Ingelheim, Teva Pharmaceutical, Daiichi Sankyo, Astellas Pharma They provide details about important activities of leading players in the competitive landscape.

The report predicts the size of the global Diabetic Neuropathy Drugs market in terms of value and volume for the forecast period 2019-2026. As per the analysis provided in the report, the global Diabetic Neuropathy Drugs market is expected to rise at a CAGR of XX % between 2019 and 2026 to reach a valuation of US$ XX million/billion by the end of 2026. In 2018, the global Diabetic Neuropathy Drugs market attained a valuation of US$_ million/billion. The market researchers deeply analyze the global Diabetic Neuropathy Drugs industry landscape and the future prospects it is anticipated to create.

This publication includes key segmentations of the global Diabetic Neuropathy Drugs market on the basis of product, application, and geography (country/region). Each segment included in the report is studied in relation to different factors such as consumption, market share, value, growth rate, and production.

Get Sample Copy of This Report:https://www.qyresearch.com/sample-form/form/2301004/global-diabetic-neuropathy-drugs-market

The comparative results provided in the report allow readers to understand the difference between players and how they are competing against each other. The research study gives a detailed view of current and future trends and opportunities of the global Diabetic Neuropathy Drugs market. Market dynamics such as drivers and restraints are explained in the most detailed and easiest manner possible with the use of tables and graphs. Interested parties are expected to find important recommendations to improve their business in the global Diabetic Neuropathy Drugs market.

Readers can understand the overall profitability margin and sales volume of various products studied in the report. The report also provides the forecasted as well as historical annual growth rate and market share of the products offered in the global Diabetic Neuropathy Drugs market. The study on end-use application of products helps to understand the market growth of the products in terms of sales.

Global Diabetic Neuropathy Drugs Market by Product: Calcium Channel Alpha-2 Delta Ligand, SNRIs and TCAs, Others

Global Diabetic Neuropathy Drugs Market by Application: , Hospitals, Drug Stores, Others

The report also focuses on the geographical analysis of the global Diabetic Neuropathy Drugs market, where important regions and countries are studied in great detail.

Global Diabetic Neuropathy Drugs Market by Geography:

Methodology

Our analysts have created the report with the use of advanced primary and secondary research methodologies.

As part of primary research, they have conducted interviews with important industry leaders and focused on market understanding and competitive analysis by reviewing relevant documents, press releases, annual reports, and key products.

For secondary research, they have taken into account the statistical data from agencies, trade associations, and government websites, internet sources, technical writings, and recent trade information.

Enquire For Customization in the Report:https://www.qyresearch.com/customize-request/form/2301004/global-diabetic-neuropathy-drugs-market

Key questions answered in the report:

Get Full Report in your Inbox within 24 Hours at USD(3350): https://www.qyresearch.com/settlement/pre/52a1fd0b8152186a4052820d2a5020fd,0,1,global-diabetic-neuropathy-drugs-market

Table Of Contents:

1 Market Overview of Diabetic Neuropathy Drugs1.1 Diabetic Neuropathy Drugs Market Overview1.1.1 Diabetic Neuropathy Drugs Product Scope1.1.2 Market Status and Outlook1.2 Global Diabetic Neuropathy Drugs Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Diabetic Neuropathy Drugs Market Size by Region (2015-2026)1.4 Global Diabetic Neuropathy Drugs Historic Market Size by Region (2015-2020)1.5 Global Diabetic Neuropathy Drugs Market Size Forecast by Region (2021-2026)1.6 Key Regions, Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.1 North America Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.2 Europe Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.4 Latin America Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa Diabetic Neuropathy Drugs Market Size YoY Growth (2015-2026) 2 Diabetic Neuropathy Drugs Market Overview by Type2.1 Global Diabetic Neuropathy Drugs Market Size by Type: 2015 VS 2020 VS 20262.2 Global Diabetic Neuropathy Drugs Historic Market Size by Type (2015-2020)2.3 Global Diabetic Neuropathy Drugs Forecasted Market Size by Type (2021-2026)2.4 Calcium Channel Alpha-2 Delta Ligand2.5 SNRIs and TCAs2.6 Others 3 Diabetic Neuropathy Drugs Market Overview by Application3.1 Global Diabetic Neuropathy Drugs Market Size by Application: 2015 VS 2020 VS 20263.2 Global Diabetic Neuropathy Drugs Historic Market Size by Application (2015-2020)3.3 Global Diabetic Neuropathy Drugs Forecasted Market Size by Application (2021-2026)3.4 Hospitals3.5 Drug Stores3.6 Others 4 Global Diabetic Neuropathy Drugs Competition Analysis by Players4.1 Global Diabetic Neuropathy Drugs Market Size by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Neuropathy Drugs as of 2019)4.3 Date of Key Manufacturers Enter into Diabetic Neuropathy Drugs Market4.4 Global Top Players Diabetic Neuropathy Drugs Headquarters and Area Served4.5 Key Players Diabetic Neuropathy Drugs Product Solution and Service4.6 Competitive Status4.6.1 Diabetic Neuropathy Drugs Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Pfizer5.1.1 Pfizer Profile5.1.2 Pfizer Main Business5.1.3 Pfizer Diabetic Neuropathy Drugs Products, Services and Solutions5.1.4 Pfizer Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.1.5 Pfizer Recent Developments5.2 Novartis5.2.1 Novartis Profile5.2.2 Novartis Main Business5.2.3 Novartis Diabetic Neuropathy Drugs Products, Services and Solutions5.2.4 Novartis Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.2.5 Novartis Recent Developments5.3 Johnson & Johnson5.5.1 Johnson & Johnson Profile5.3.2 Johnson & Johnson Main Business5.3.3 Johnson & Johnson Diabetic Neuropathy Drugs Products, Services and Solutions5.3.4 Johnson & Johnson Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.3.5 Eli Lilly Recent Developments5.4 Eli Lilly5.4.1 Eli Lilly Profile5.4.2 Eli Lilly Main Business5.4.3 Eli Lilly Diabetic Neuropathy Drugs Products, Services and Solutions5.4.4 Eli Lilly Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.4.5 Eli Lilly Recent Developments5.5 GlaxoSmithKline5.5.1 GlaxoSmithKline Profile5.5.2 GlaxoSmithKline Main Business5.5.3 GlaxoSmithKline Diabetic Neuropathy Drugs Products, Services and Solutions5.5.4 GlaxoSmithKline Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.5.5 GlaxoSmithKline Recent Developments5.6 Boehringer Ingelheim5.6.1 Boehringer Ingelheim Profile5.6.2 Boehringer Ingelheim Main Business5.6.3 Boehringer Ingelheim Diabetic Neuropathy Drugs Products, Services and Solutions5.6.4 Boehringer Ingelheim Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.6.5 Boehringer Ingelheim Recent Developments5.7 Teva Pharmaceutical5.7.1 Teva Pharmaceutical Profile5.7.2 Teva Pharmaceutical Main Business5.7.3 Teva Pharmaceutical Diabetic Neuropathy Drugs Products, Services and Solutions5.7.4 Teva Pharmaceutical Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.7.5 Teva Pharmaceutical Recent Developments5.8 Daiichi Sankyo5.8.1 Daiichi Sankyo Profile5.8.2 Daiichi Sankyo Main Business5.8.3 Daiichi Sankyo Diabetic Neuropathy Drugs Products, Services and Solutions5.8.4 Daiichi Sankyo Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.8.5 Daiichi Sankyo Recent Developments5.9 Astellas Pharma5.9.1 Astellas Pharma Profile5.9.2 Astellas Pharma Main Business5.9.3 Astellas Pharma Diabetic Neuropathy Drugs Products, Services and Solutions5.9.4 Astellas Pharma Diabetic Neuropathy Drugs Revenue (US$ Million) & (2015-2020)5.9.5 Astellas Pharma Recent Developments 6 North America6.1 North America Diabetic Neuropathy Drugs Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe Diabetic Neuropathy Drugs Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific Diabetic Neuropathy Drugs Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America Diabetic Neuropathy Drugs Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa Diabetic Neuropathy Drugs Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 Diabetic Neuropathy Drugs Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read more:
Diabetic Neuropathy Drugs Market Growth, Industry Analysis, Size and Share 2026| Pfizer, Novartis, Johnson & Johnson - The Haitian-Caribbean News...

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Lebers Hereditary Optic Neuropathy Drug Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Lebers Hereditary Optic Neuropathy Drug Market Overview

The Lebers Hereditary Optic Neuropathy Drug Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Lebers Hereditary Optic Neuropathy Drug market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Lebers Hereditary Optic Neuropathy Drug Market: Competitive Landscape

The Lebers Hereditary Optic Neuropathy Drug Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Lebers Hereditary Optic Neuropathy Drug Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Lebers Hereditary Optic Neuropathy Drug Market Segment by Type:

Lebers Hereditary Optic Neuropathy Drug Market Segment by Application:

Lebers Hereditary Optic Neuropathy Drug Market Regional overview:

In the report, experts analyze and forecast the Lebers Hereditary Optic Neuropathy Drug market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Lebers Hereditary Optic Neuropathy Drug Market Report:

Outlook analysis of the Lebers Hereditary Optic Neuropathy Drug market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Lebers Hereditary Optic Neuropathy Drug market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

More here:
Leber's Hereditary Optic Neuropathy Drug Market Size, Analysis, Growth, Trends, Outlook And Forecast By 2027 - The Haitian-Caribbean News Network

A neurological horror story lies at the centre of Xavier Alfords chilling, stoic and finally revitalising documentary, part of the BBC Storyville strand. Guillain-Barr syndrome is a rare condition that can strike without warning, where the immune system attacks the nerves, sometimes leaving the victim completely paralysed. A passenger in your own body or a weird wormhole you dream all the time is how one person interviewed sums it up though he subsequently recovers.

But director Alford has to suffer a second horror: knowing his fate. Alfords illness, known as multifocal motor neuropathy, is related to Guillain-Barr syndrome but is progressive over many years, palsying the outer extremities first we first see him struggling to grasp his camera. Being, as one clinician points out, the sort of person who wants to know, Alford resolves to learn as much as possible about what awaits him. In what is obviously a therapeutic quest, he spends the film meeting other people in different phases of this chronic neuropathy.

At one point he confronts the worst-case scenario: a patient called Rob, who loses even the ability to communicate with his left eyelid, and has his life support switched off. His wife, while being told it is just a medical decision for which she bears no responsibility, is effectively asked to agree that it is what he would have wanted.

Though the case studies are interesting, Alfords film becomes truly illuminating as he probes this ethical territory in his own life. What is the level of responsibility he has the right to expect of his wife, Anna, and children and his own obligations to communicate his inner experience to them? The film makes this possible for him, but his other half virtually refusing to appear on camera questions if this is appropriate. Who can say? Whats certain is that this bleak, patient inquest is relevant far beyond one rare syndrome.

Locked In: Breaking the Silence is on BFI Player and BBC iPlayer from 30 November.

Go here to see the original:
Locked In: Breaking the Silence review life-affirming story of a devastating illness - The Guardian

EDINBURGH, Scotland & KIBBUTZ SHEFAYIM, Israel--(BUSINESS WIRE)--Scottish digital transformation consultancy Storm ID and Israeli AI start-up Zebra Medical Vision have won a UK-Israel research and development competition with a proposal for a revolutionary, machine learning-driven model for early detection and prevention of osteoporosis to improve patient care and reduce healthcare costs. The collaboration will involve close engagement with clinical teams in NHS Greater Glasgow and Clyde and Assuta Medical Centers.

Osteoporosis is a major public health concern that continues to grow in worldwide importance. Fragility fractures, defined as insufficiency fractures not related to high-impact trauma, are the major complication of this underdiagnosed and undertreated condition. Major osteoporotic fractures result in substantial morbidity and mortality, particularly for hip fractures, which is a major concern for an aging population.

Working in partnership, Storm ID and Zebra Medical Vision are developing a preventative care solution to identify people at risk of osteoporosis. Using ML/AI methodologies, the solution will analyze medical imaging data and patient records to help clinical teams identify and treat people with risk of fractures before they happen.

An international, multidisciplinary team of clinicians, data scientists and computer scientists will work together over 2 years, running clinical trials, implementing the solution in both NHS Greater Glasgow and Clyde and Assuta Medical Centers. The project is co-funded in part by the UK and Israel under the EUREKA framework to foster industrial research collaboration between the UK and Israel.

Paul McGinness, Director at Storm ID said: Were aiming to combine the powerful data exchange capabilities of our own Lenus Health Platform with the machine learning models developed by Zebra Medical Vision to transform osteoporosis screening. By predicting ahead of time the potential risk of bone fracture , we can intervene earlier to treat and manage the risk, which is better for the patient and for the health system.

Ohad Arazi, CEO at Zebra Medical Vision said: Were honored to enhance our collaboration with the NHS and Assuta Medical hospital through this incredible initiative, allowing Zebra Meds solutions to even more widely spread in the UK and Israeli healthcare facilities to bring earlier identification and treatment of patients at risk of a break, which in turn will help healthcare payers and providers.

David Lowe, Emergency Consultant, NHS Greater Glasgow and Clyde, and Clinical Lead, West of Scotland Innovation Hub, said: We are pleased to partner on the development of this innovative new solution for osteoporosis patients through the expertise of the West of Scotland Innovation Hub. This is another example of a successful collaboration between industry and the NHS to move forward innovative healthcare. Our clinical teams at NHS Greater Glasgow and Clyde will support the aim of this project to ultimately identify and treat patients with increased risk of bone breakage before it happens.

Dr. Michal Guindy, Head of Imaging and Innovation at Assuta said: "Being able to re-analyze information from patient records and imaging is an important advantage of modern artificial intelligence. As a center of excellence, performing over 200,000 CTs annually, Assuta is excited to play a significant role in early detection of osteoporosis. By analyzing studies that were done for other clinical indications, we can leverage pre-existing data to help prevent fractures and contribute to solving a public health challenge of growing concern."

Read more on Zebra Medical Visions blog.

About Storm ID and Lenus Health

Storm ID is a digital transformation delivery partner for the healthcare sector.

It developed the Lenus Health Platform to support delivery of new digital health solutions that are continuous, preventative and participatory, and which help transform care pathways.

Lenus enables patient generated health data from digital technologies and consumer health tech such as apps, sensors and wearables to be shared with healthcare professionals and machine learning models to provide decision support, enabling targeted interventions to happen in the community. It supports solutions that reduce unnecessary and expensive hospital admissions including face-to-face appointments, improve patient engagement with their own health and wellbeing and reduce duplication and unnecessary processes through user managed access to patient data.

About Zebra Medical Vision

Zebra Medical Vision provides radiologists with the tools needed to make the next leap in patient care. The demand for medical imaging solutions is continuously increasing, outpacing the supply of qualified radiologists and stretching them to produce more output, without compromising patient care. Only by adopting new technology that significantly enhances the capabilities of radiologists, can this crisis be mitigated. Zebra-Med is empowering radiologists with its revolutionary AI1 offering which helps health providers manage the ever increasing workload without compromising quality.

About NHS Greater Glasgow and Clyde

NHS Greater Glasgow and Clyde is one of 14 regional NHS Boards in Scotland, serving a population of 1.14 million and employing around 39,000 staff. It is the largest NHS organisation in Scotland and one of the largest in the UK.

About Assuta Medical Centers

Assuta Medical Centers is Israels largest and leading private medical solution network comprising seven hospitals and clinics across Israel and providing innovative surgeries and diagnostic procedures in all fields of medicine. Assutas Imaging Institute is the most advanced of its type in Israel and has a team of leading radiologists and nuclear medicine specialists. The Institute offers patients the latest innovations in imaging technology, including advanced CT and PET-CT, MRI, PET-MR, and two-head nuclear imaging camera test results are integrated with other clinical data to enhance the accuracy of the findings. The Institute treats more than 600,000 patients annually.

About EUREKA

EUREKA is an intergovernmental network launched in 1985. Its aim is to support market-oriented R&D and innovation projects by industry, research centres and universities across all technological sectors. EUREKA has 41 full members, including the European Union (represented by the European Commission), 1 partner country (South Korea) and 4 associated members (Argentina, Canada, Chile, South Africa). All 27 EU Member States are also members of EUREKA.

The UK-Israel call for proposals was a joint initiative of Innovate UK and the Israel Innovation Authority based upon the 2017 memorandum of understanding on industrial collaboration between the 2 countries.

Continue reading here:
Storm ID and Zebra Medical Vision to Co-Develop Revolutionary New AI Based Osteoporosis Prevention Solution as Part Of UK-Israel Collaboration -...

Medical experts say preparation and additional materials are making it much easier for front line workers to manage the surge in daily hospitalizations.

NIAGARA COUNTY, N.Y. As the Western New York community continues to follow this trend of rapidly increasing COVID-19 cases and daily hospitalizations, concerns and worry over hospital capacity and lack of resources also continue to rise.

Despite the increasing rise in hospitalizations, local medical experts say the method of care during this surge is significantly different than last spring thanks to the abundance of knowledge, new drug treatments, necessary materials and, perhaps most importantly, a solidified and legitimate plan.

At the start of the pandemic everyone, from lawmakers and healthcare workers, to everyday citizens, was taken by surprise. There was no blueprint on how to a navigate and treat something like this virus, despite other historic pandemics, the novel coronavirus is unique in nature.

Joe Ruffolo is the CEO of Niagara Falls Memorial Medical Center and has been with his team on the front lines since early spring. Ruffolo says, things inside the medical center may look busier as of late, but things feel different.

We have more tools in the tool kit this time around, Ruffolo says.

Another differentiating factor this time around new trends.

We're seeing a lot of younger people being tested positive, where in March and April, there was a significant portion of elderly people that were impacted with the COVID virus, Ruffalo points out.

Ruffolo tells 2 On Your Side, while more patients are coming in, less of them need ventilators. Which frees up a significant amount of space for those high-risk patients in need of intensive care.

Right now, he says, the medical center is seeing (on average) four to eight COVID patients a day. More of them appear relatively healthy, between the ages of 25 and 50, and are responding well to drug therapies that enable them to transfer out of the hospital quicker than before.

Weve developed an outpatient setting where we can bring them in, in a safe environment, provide drug therapy, that would enable them to recover sooner, Ruffolo says.

Another benefit, Ruffolo says, is the abundance of materials. Unlike the first wave, Ruffolos team has more PPE, face masks, gowns, protective face wear and back up beds so theres no worry that hospital doors will be forced to close.

We have over fifty additional beds that we could put in place in various areas for designated COVID clusters or pods, he says.

Though Niagara Countys numbers are significantly lower in comparison to other parts of Western New York, Ruffolo says his entire team, top to bottom, is doing everything possible to stay ahead of the surge.

The best medicine, is always preventative medicine, he says.

Like many of his peers, Ruffolo encourages the public to continue following CDC guidelines and public safety measures. Because, while at the moment hospital systems are managing, its possible for the past to become the present, especially when dealing with fluid medical emergencies like this one.

View post:
Hospitals work hard to stay ahead of spike in COVID-19 cases across Western New York - WGRZ.com

HONG KONG, Nov. 26, 2020 /PRNewswire/ -- Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; SEHK:0575.HK)'s Deep Longevity, Inc, a company subject to a conditional acquisition by the Group which is a pioneer in deep biomarkers of aging and longevity today announced a collaboration with My Care Express Merrillville to deploy an extensive range of AI-powered aging clocks. Deep Longevity is to develop and provide the customized predictors of human biological age to the network of My Care Express clinicians and to provide a training program in longevity medicine.

Deep Longevityaging clocks are supported by a number of academic publications summarized in a recent review titled "BioHorology and biomarkers of aging: Current state-of-the-art, challenges and opportunities"

My Care Express Merrillville has been a provider of preventative and total health care to its patients since it opened. My Care Express has a unique approach to wellness and longevity by helping patients establish wellness goals to live happier, healthier and longer lives. Deep Longevity and My Care Express will partner to see the impact that the utilization of aging clocks has on their patients. "We have always believed that the more information our patients have regarding their health, the better choices they will make. We believe that implementing aging clocks will give our patients a better understanding of their current health and help them achieve their wellness goals", said Dr. Faiz Shareef.

In the scope of the partnership My Care Express physicians will be trained in deep aging clocks and will be able to provide their customers with AgeMetric reports and engage in advanced research to assess the performance of aging clocks in the context of their wellness journey.

"The traditional approach to preventative medicine is focused on preventing disease by diagnosing the symptoms early or reducing the risks of disease. The AI-guided longevity medicine goes much further than that and is focusing on tracking the person's rates of aging at many levels, identification of longevity bottlenecks, and utilizing the latest advances in science and technology to slow down or reverse biological and psychological aging. We are very happy to have My Care Express join the rapidly growing network of our research and clinical partners focused on providing customers with extra years of productive and happy life", said Alex Zhavoronkov, Chief Longevity Officer of Deep Longevity Inc.

About Deep Longevity

Deep Longevity is subject to a conditional acquisition by Regent Pacific Group Limited (SEHK:0575.HK), a public company whose securities are listed on The Stock Exchange of Hong Kong Limited. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS) solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other experts AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.

http://longevity.ai/

About Regent Pacific (SEHK: 0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness, and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.

http://www.regentpac.com/

About My Care Express Merrillville

My Care Express Merrillville is a clinic in Northwest Indiana that provides primary and urgent care with a focus on preventative medicine. My Care Express believes in a proactive approach to healthcare by providing its patients with tools that will help them live longer healthier lives. Located on the border of Indiana and Illinois, My Care Express has a dynamic and diverse practice. For more information visit mycareexpressclinic.com

Here is the original post:
Deep Longevity Adds Partnership with My Care Express in Merrillville To Add Biomarkers of Aging and Longevity - WFMZ Allentown

Dr. David Katz, Preventive Medicine Specialist & True Health Initiative President, joined Yahoo Finance Live to discuss the surging number of COVID-19 cases in the U.S. and how the Thanksgiving holiday may impact case numbers.

- We're also breaking records, but not in a good way, when it comes to COVID-19 and the pandemic. Let's invite into the stream, Dr. David Katz, preventative medicine specialist and True Health Initiative president. Good to have you here. We keep hearing the warnings from the Centers for Disease Control-- stay at home, don't travel for Thanksgiving. We see one million people going through TSA checkpoints at airports every day. It seems as if we're building up two weeks from now for something that could really, I'm going to use the word horrific-- something that could be horrific, especially for people who work in the medical profession.

DAVID KATZ: Well, good to be with you, Adam. Happy holiday in spite of it all. And I hope not. You know, in some sense, it's pretty horrific already. We have cases rising all around the country. And in those parts of the country that were not very hard hit already-- and I happen to be in one-- you are, as well, New York City, Connecticut, the Northeast-- we were pretty hard hit over the summer and in the spring. And we're not seeing quite a steeper rise in hospitalization here as many other parts of the country. But much of the country is. So it's pretty bad, already.

I think the question about the holiday is, how careful are people being? Are they getting tested? There's much more testing available than there was before. I think many people are testing before they get together with family. That's not as good as staying home, but it's certainly better than not taking any precautions. I've spoken to my extended social network to find out what are the different plants. I imagine you've done the same, right? Not everybody's doing the same thing.

Some people are staying home. Some are gathering, but in much smaller groups. Many modifications, right? Variations on the theme. So I think if people are suitably careful, then it may be there is no post-holiday surge in the surge that we already have. We're kind of already there. We're not going to know, though, until those couple of weeks roll by. And, you know, there's been so much unpredictability in the pandemic. It's a new pathogen. We're learning by going where we have to go.

Story continues

The best advice, of course, is to be very careful. The most carefully you can be is to stay put. The next most careful would be don't expose yourself to anybody who might transmit the virus to you. Don't expose yourself to anybody who might get the virus from you.

- Dr. Katz, how would you compare what we're seeing now to what we saw last spring? Are the numbers that we're seeing now and the extent of it more alarming?

DAVID KATZ: It's a very similar phenomenon, Seana. It's just more widespread around the country. It was highly concentrated in the Northeast, initially-- in Detroit, in and around Seattle. There are few parts of the country where the virus got a foothold, and it spread. And importantly, it spread across risk tiers. So what we're seeing now is a fairly massive level of transmission, much of it among people who are asymptomatic or minimally symptomatic.

This slight departure, perhaps, from some of my colleagues in public health-- that doesn't bother me all that much. What bothers me is when that group so young healthy people get together with people in higher risk tiers. People with diabetes, people with obesity, heart disease, people over 70, people over 80. Because when they get this virus. They're prone to get very sick. And when we see cases go up without hospitalization going up, that may be circulation among young healthy people-- that's not so dire.

When we see hospitalization go up, ICU populations go up, and death counts go up-- and we're seeing that in much of the country now-- that means we're transmitting the virus to a more vulnerable group. And that's very concerning. So it's not more concentrated than it was in New York, but it's now more widespread around the country. And frankly, similar phenomena in other parts of the world, too. Yeah, Adam, sorry.

- Dr. Katz, we have to wrap up, but really, this is a serious question, because you talked about prevention. Do you have advice here, Doctor? You wear masks all the time, we're all now wearing masks. Those of us who wear glasses, the dreaded fogging up of the glasses-- is there a trick for the mask? Because I know nobody who's been able to solve this.

DAVID KATZ: I wish I had one. It is so annoying, isn't it? Yeah, so listen, I think the best I can say is that you know given the consequences of transmitting this virus to people who are frail or elderly, the minor inconvenience of foggy glasses is something we just need to put up with. But no, actually, we'll have to talk later If either of us finds a solution, we'll share it with the other one. But I'd love to know one, too.

- I actually Scotch taped the top of the-- that worked until you start sweating if you're running or walking. And then--

DAVID KATZ: You know, I'm a skier. You know, we have goggles and anti fog wise. So maybe we should just wear-- we just go all in and wear goggles with our masks. Maybe that would work. I don't know, I haven't tried it.

- Well, you've helped clear the fog here for all of us today. Thank you very much. Dr. David Katz, preventative medicine specialist and True Health Initiative president. Thank you for joining us on Yahoo Finance Live.

Link:
Getting a COVID-19 test ahead of Thanksgiving travel is 'not as good as staying home: Doctor - Yahoo News

Teens who participate in in-person after-school activities such as sports, arts, and community programs show higher levels of life satisfaction and optimism, according to a study published in Preventative Medicine. The teens surveyed also reported lower screen time a habit associated with higher levels of anxiety and depression.

Teens tend to engage in both extracurricular activities and screen time. Therefore, the authors wanted to examine time use of both in relation to mental health indicators.

The study included self-reported data from more than 28,000 7th grade students in British Columbia, Canada, who completed a survey in 2014/2015 and 2017/2018.

Of the teens surveyed, 14.47% did not participate in extracurricular activities. For screen time, 48% reported less than 2 hours a day and 47.52% reported 2 hours or more per day.

Extracurricular participation was negatively related to screen time (2 = 573.37, df = 1, P < .001); nonparticipants were more likely to report higher levels of screen time than participants. Among nonparticipants, 66.63% reported longer screen time. Among the teens who participated in extracurricular activities, the number who participated in longer screen time dropped to 46.28%.

Extracurricular participation (est. = 0.23, 99% CI [0.17, 0.28]) and shorter screen time (est. = 0.29, 99% CI [0.20, 0.37]) were associated with higher levels of satisfaction with life. Extracurricular participation (est. = 0.25, 99% CI [0.20, 0.30]) and shorter screen time (est. = 0.31, 99% CI [0.23, 0.40]) were positively associated with optimism.

The teens who did not participate in extracurricular activities and who reported longer screen time also reported higher negative mental health scores.

This study had some limitations. Data were cross-sectional and causality cannot be implied. Mental health measures were not diagnostic or clinical screening measures. And, screen time did not distinguish between forms of screen use, such as smartphone and computer, or type, such as social media.

The researchers also found differences between boys and girls. Longer hours of screen time were consistently more detrimental for the mental health of girls than for boys in this study. In other words, the protective nature of shorter screen time was more important for girls than for boys mental health, the authors concluded.

This finding is consistent with previous research suggesting that long hours of internet use was more common among girls (but not boys) with major depressive symptomatology compared to girls with no or minor depressive symptomatology.

Reference

Oberle E, Ji XR, Kerai S, Guhn M, Schonert-Reichl KA, Gadermann AM. Screen time and extracurricular activities as risk and protective factors for mental health in adolescence: A population-level study. Prev Med. 2020 Oct 16;141:106291. doi: 10.1016/j.ypmed.2020.106291

View post:
Real-Life Activities Lead to Happier Teens - Psychiatry Advisor

Shawna De La Rosa | Nov 23, 2020

Several health care bills are slated for consideration when Virginia legislative sessions resume Jan. 13. Some of the highlights are listed below.

Get the latest state-specific policy intelligence for the health care sector delivered to your inbox.

HB188: Health care service estimates

Health care services and payment estimates will be considered in HB188. The bill would require hospitals and practitioners licensed by the Board of Medicine to allow a patient to receive an estimate for a nonemergency procedure or test no later than week after scheduling the procedure. Currently, only hospitals are required to provide those estimates.

HB526 Reproductive health coverage

The HB526 would require health benefit plans to cover the costs of specified health care services, drugs, devices, products and procedures related to reproductive health, including well women preventative visits, counseling for sexually transmitted infections, screenings for certain conditions, folic acid supplements, breastfeeding support, breast cancer chemoprevention counseling, contraception, voluntary sterilization and all other treatments that must be covered under federal law as of Jan. 1, 2019.

HB530 Health plans

The Department of Medical Assistance Services, in collaboration with the State Corporation Commission, will be required to contract with health carriers to offer qualified health plans on the health benefit exchange beginning Jan. 1, 2022, if HB 530 passes.

HB579 Mammogram coverage

House Bill 579 would require health insurers to provide coverage for low-dose screening mammograms after Jan. 1, 2021, if the individual has a family history of breast cancer. If an individual has a family history of breast cancer, insurers would have to cover annual mammograms from age 30 to 49 and biannual mammograms starting at age 50.

HB1036 Preventative mental health screenings

Preventative mental health screenings will be covered for outpatient mental health patients if HB 1036 passes. It would require a health carrier to provide coverage as a preventative service for at least six annual therapy or counseling outpatient screenings or visits with a licensed mental health professional for the early detection or prevention of mental illness. Health carriers would be prohibited from imposing cost-sharing requirements for mandated preventative services.

HB1331 Provider contract provisions

House Bill 1331 would prohibit a health carrier that offers a managed care plan from entering into, extending or renewing a provider contract with a facility unless the provider contract contains certain provisions. Each health provider that provides emergency services at the facility of an in-network provider has agreed to have the reimbursement from the health carrier included as part of the health carriers payment to the facility. It also requires that the health carrier cant be billed separately for emergency or ancillary services provided at the facility. This applies to any laboratory or diagnostic service provided at the facility which is in-network or for the referral to an in-network provider.

See the article here:
Health care bills already slated for 2021 session - State of Reform - State of Reform

Even if you're downsizing your dinner, here are some easy swaps to make the traditional holiday recipes healthier

OHIO, USA All year long I have been counting down to Thanksgiving. The turkey, the dressing and we cant forget about the desserts! Oh, and we cant forget about the real reason for the holiday - getting together with friends and family.

And though some of us are downsizing our dinner tables, or moving to a virtual celebration, most of us are still preparing those traditional recipes.

But this year, I have a new perspective thanks to this "The New You" journey, and Im learning that behind all of that love of family and food can be something thats a danger to your health. So, I went back to my new friend Jim Perko, Executive Chef of Cleveland Clinic's Wellness & Preventative Medicine.

"Studies show everybody will consume between 3-5,000 calories between the food and drinks at holiday thanksgiving meal. Yeah, thats a lot," Jim told me.

But, Jim says it is possible to survive this holiday without gaining weight.

"Some of the pitfalls are, you dont want to starve before the meal because youre just going to overeat. You want to make sure you eat slowly, chew your food well. Give your brain time to catch up with your stomach."

Studies have shown that our overeating can stretch our stomachs leading to weight gain.

And when it comes to the meal, it starts with the turkey. Jim says, stick with the white meat, because there is much more saturated fat in the skin, leg and thigh.

But how you cook the turkey can make a big difference too.

"If you put the dressing between the skin and the breast of the meat, the flesh what happens is the dressing isnt going to overcook. It Is going to protect the jewel that solid muscle of white meat. By the time the white meat is done, it helps it keep it moist," Jim said.

He also suggests that instead of using a gravy or sugar - try adding fruit instead.

"Pears and apples. Try moistening that dressing with the fruit and its adding flavors I dont have to pour a lot of gravy and roux on top of it," Jim explained.

Last week, I tried Jims Mac and Cheese-less recipe, another great option to add to the meal - trust me, it's actually good!

"It is totally plant based. The thickening agent is sweet potatoes and cashews and 100% whole grain pasta. There was no cheese added. No saturated fat," Jim reminded me.

Another staple in my family is ham, but Jim says, it's not the best choice.

"When you have ham its cured with nitrates and salts so its better to just avoid anything cured salty," he explained.

And, if you still have room for dessert at the end of the meal, Jim said, try to just have a taste.

"Maple syrup makes you want more maple syrup. Sweet wants more. So trying to go to make less it will be just enough to let you satisfy your sweet tooth."

Jim was kind enough to share some of his favorite holiday recipes from "The What to Eat When Cookbook."

INGREDIENTS: Four cups water, one cup (5 ounces) raw cashews, 12 ounces 100% whole wheat short elbow pasta, 6 cups (about 28 ounces)sweet potato, peeled, cut into 1/2 to 3/4 inch cubes, 2 teaspoons (or more) mild hot sauce such as Cholula, 1 teaspoon Dijon mustard , 3/4 tablespoon kosher salt, 1/4 teaspoon freshly ground black pepper, 1/4 teaspoon ground nutmeg, 1 pinch cayenne pepper.

VEGAN HOLIDAY DRESSING/STUFFING

MAKES: Fourteen cup serving

INGREDIENTS: 8 cups - 100% Whole Grain Dried Bread, dice, 3 tablespoon Parsley chopped, 2 tablespoon Extra Virgin Olive Oil, teaspoon Salt, 1/8 teaspoon Pepper, 1 teaspoon Poultry Seasoning, 1 teaspoon Sage, 2 cups Vegetable Stock, 1 cup Leeks small dice, 1 cup Onion small dice, cup Celery small dice, cup Carrot small dice, cup Toasted Pecans, cup Toasted Walnuts, 1 cup Unsweetened Pineapple Juice, 1 cup Apples small dice, 1 cup Pears small dice

Wash and small dice the apple placing them in a bowl of pineapple juice to prevent browning. Drain the apples, reserving the liquid. Wash pears and small dice placing and toss them in the reserved pineapple juice to prevent browning, add apples to bowl and set aside. Heat a non-stick skillet and add oil, then add onions season with salt, pepper and cook on medium heat until onions just turn transparent. Add celery, carrots and cook until tender. Add the leeks, cook for 5 minutes, then turn off heat and set pan aside. In a large mixing bowl, combine bread with sauted vegetables, add parsley, poultry seasoning, and sage - mix well.

Add vegetable stock and mix well. Add cut fruit in pineapple juice, nuts and mix well. Use a 2 quart casserole dish that has been wiped with a light film of extra virgin olive oil to prevent sticking; add dressing. Cover with plastic wrap then aluminum foil. Bake for 30 minutes in a pre-heated 400 degree oven.

RUTABAGA, CARROT AND SWEET POTATO MASH

MAKES: 6 Servings Serving Size:cup

INGREDIENTS:1 cups rutabaga - peeled and diced, 1 cups carrot - peeled and diced, 1 cups sweet potatoes - peeled and diced, 32 ounces water, teaspoon salt, teaspoon black pepper

In large saucepan combine rutabaga with vegetable broth and simmer until tender, about 30 minutes. Add carrots and continue simmering until carrots are almost tender, about 5 minutes. Add sweet potatoes and simmer until all vegetables are tender, about another 10 minutes.

Drain the vegetables into a bowl while reserving the liquid. Place liquid back in saucepan, reduce to cup. Turn off heat and add vegetables from bowl back to sauce pan along with salt and pepper. With a potato masher, mash vegetables with reduced liquid until a coarse consistency. If mash needs to be heated more, just heat in saucepan until desired temperature. Remove and serve.

NUTRITIONAL INFORMATION PER SERVING:

For increased flavor, cook vegetables in vegetable broth instead of water.

CULINARY MEDICINE HEALTH TIP:

This recipe shows how to create intensely flavorful cooking liquid by using a vegetable skimmer to remove vegetables after cooking. One can retain and reduce cooking liquid for a 100% natural and extremely flavorful broth that can be added back to the vegetables or used in another application.

PAPAS PUMPKIN PIE-LESS

PREP: 25 minutes, plus overnight soaking

INGREDIENTS:1 cup raw cashews, 4 cups water, 1 sweet potato (14 to 16 ounces), 1 large ripe banana broken into chunks, cup pure unsweetened almond butter, 6 tablespoons raisin reduction, cup unsweetened almond milk, 2 teaspoons vanilla extract, 1 can (15-ounce) pure pumpkin, 5 teaspoons pure maple syrup, 1 teaspoons ground cinnamon, teaspoon ground ginger, teaspoon ground nutmeg

Go here to see the original:
The New You: How to have a healthier Thanksgiving meal - WKYC.com

An online webinar, the eighth Coronavirus (COVID-19) Symposium is sponsored byNew York Medical College of the Touro College and University System. Continuing Education credits are available upon request.

A presentation by the Center for Disaster Medicine of New York Medical College of the Touro College and University System.

Alan Kadish, M.D.Cardiologist | President, Touro College and University System | President, New York Medical College

Edward C. Halperin, M.D., M.A.Chancellor and CEO, Professor of Radiation Oncology, Pediatrics and History, New York Medical College | Provost for Biomedical Affairs, Touro College and University System

by Robert Amler, M.D., MBADean, School of Health Sciences and Practice, Vice President for Government Affairs, New York Medical College | Former Regional Health Administrator, U.S. Department of Health and Human Services | Former Medical Epidemiologist, Centers for Disease Control and Prevention (CDC)

by Sherlita Amler, M.D., M.S., FAAPCommissioner of Health, Westchester County, NY

by Mill Etienne, M.D., M.P.H., FAAN, FAESAssociate Dean for Student Affairs, Associate Professor of Neurology, School of Medicine House Advisory Dean, New York Medical College

by Kathleen DiCaprio, Ph.D.Assistant Professor of Medical Microbiology and Immunology, Touro College of Osteopathic Medicine

by Tami Hendriksz, DOProfessor and Associate Dean of Academic Affairs, Touro University California College of Osteopathic Medicine

by Marisa A. Montecalvo, M.D. Medical Director, Health Services, Professor of Medicine, New York Medical College | Infectious Disease Specialist

by Neil Schluger, M.D. Barbara and William Rosenthal Chair of the Department of Medicine, School of Medicine, New York Medical College | Director of Medicine, Westchester Medical Center

by Edward C. Halperin, M.D., M.A.Chancellor and CEO, New York Medical College | Provost for Biomedical Affairs, Touro College and University System

Hosted by Alan Kadish, M.D.Cardiologist | President, Touro College and University System | President, New York Medical College

Responses will be provided to the questions submitted in advance of the webinar. Questions may be submitted to covid19updates@touro.edu

Register in advance for this webinar

This meeting has been approved for 1.5 CME credits by the Office of Continuing Medical Education, New York Medical College free of charge as a community service to our Healthcare Providers.

Accreditation Statement: New York Medical College is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

New York Medical College designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support: There is no outside funding for this activity.

Disclosures: All activity faculty and planners participating in continuing medical education activities provided by New York Medical College are expected to disclose to the audience any significant support or substantial relationship(s) with commercial entities whose products are discussed in their presentation and/or with any commercial supporters of the activity.

Read the original:
Eighth Symposium on COVID-19: What Have We Learned? How Can We Use What We Have Learned? - Touro College News

EDITORS NOTE: During this season of Thanksgiving, we are reaching out to our writers and readers for inspiration. I dont need to repeat the theme of this years trials and tribulations we plan to provide you with thoughtful, uplifting reading over the next few weeks and throughout the holidays. Lets celebrate thanks and giving. What are you thankful for? Give thanks, and lets all be thankful that we live in this very special corner of the world in a community that cares for EVERYONE. Pioneer contributor Julie Chick shares her love for the outdoors and the science behind the connection to our well-being, and introduces us to another gifted healer in our backyard and the benefits of connecting outside. Share your Thanks & Giving to editor@tillamookcountypioneer.net. Watch for more about La Vida Pacifica and more thanks & giving.

By Sarah Reese and Julie Chick

She says she experienced severe depression at age 13 until she developed a strong love for the mountains through snowboarding a few of years later. Ultimately, without exaggeration, she credits this love of the outdoors for saving her life and setting her on a lifelong course of healing and transformation.As I recently walked a fall dappled trail with Nehalem resident and licensed Acupuncturist and Herbalist, Sarah Reese, LAc, we continued the discussion about the role the outdoors can play on our overall and mental health. Throughout college Sarah cultivated her passion for being in nature through outdoor recreation, and now as an adult says, Being active in the wilderness brings me home within myself and affords me enhanced joy, confidence, peacefulness, and personal empowerment. It has aligned me with my souls purpose and generally made me more comfortable in my own skin. Being in nature allows me to be me to let the soft animal of [my] body love what it loves as Mary Oliver puts it in her poem Wild Geese .

Sarahs educational background is in Classical Chinese Medicine and her interest in the Healing Arts began initially through Transpersonal Counseling Psychology, but ultimately, she received her formal training in East Asian medicine because of her affinity for Holistic medicine and the way it addresses the body, mind and Spirit. The way that she practices medicine is rooted in Daoist philosophy which expresses our intrinsic connection to nature and its cycles, and elucidates the concept that we are as much in the universe as the universe is within us. We are not only affected by nature and its cycles, but we are nature and its cycles. We cannot be separated from our ecology.

Sarah sees the current times we are in as an opportunity to utilize preventative medicine to fortify the immune system, and also to employ natural medicine to combat illness when our bodies are out of balance. For example, simple strategies like getting enough rest, reducing stress, practicing conscious breathing and mindfulness, and moving our bodies in nature all restore balance to our lives and create a state of wellbeing in our bodies that makes it exponentially less likely to become ill. A commitment to self-care now significantly reduces our recovery time if we do become ill. Numerous studies in the US and all over the world have proven the health benefits of being outdoors in green spaces, theres no questions that we can affect and improve our general health profile just by simply being outdoors. Additionally, there is mounting research making the connection between our internal biome (gut bacteria) and mental health.The best way to enjoy the healing powers of nature is to find your own sources of joy and prioritize those. Something as simple as a walk on the beach or around the block, or simply just getting outdoors, can boost your mood, reduce stress and set you on a path of wellness. For the sake of the world and our collective wellness add time outdoors to the list, or if you already know you enjoy time in nature, move that to the top of the list.According to Why green spaces are good for grey matter,* walking between busy urban environments and green spaces triggers changes in levels of excitement, engagement and frustration in the brain, a study of older people has found. Sarah suggests, Now more than ever, its vitally important to reconnect with nature and get ourselves outdoors when we can.Sarahs healing practice is called La Vida Pacifica, which means The Peaceful Life in Spanish, and is also an homage to the beautiful North Pacific Coast that we all love. Through La Vida Pacifica she offers mentorship for people searching for guidance, support, and accountability as they navigate their path of wellbeing. Since there is no one size fits all in Holistic wellness, it has always been her mission to connect with people wherever they are on their healing journey and help them realign with their personal Truth. She serves those answering the call for soul-level work who want to develop their intuition in order to live their lives with more creativity, authenticity and vitality. She does private sessions and consultations (over the phone) with an emphasis on Spirit, Mind, Body integration, and incorporates the outdoors when she can. Sarahs email: lavidapacifica@gmail.com

*University of York. Why green spaces are good for grey matter. ScienceDaily. ScienceDaily, 10 April 2017. Related Post

See original here:
Thanks & Giving: Mental Health and the Outdoors Tillamook County Pioneer - Tillamook County Pioneer

The phrase herd immunity comes up often in coronavirus discussions. Those who toss around the term, including some politicians, say its a way to potentially end the pandemic. But herd immunity is actually a complex concept that health experts say is often misunderstoodand, focusing on hand washing, social distancing and mask wearing remains the best way to stop the spread of COVID-19.

But what is herd immunity? In simple terms, population (aka herd immunity) is one that works through achieving a threshold immunity at the population level that is able to cut the transmission chain and cycle of a given infectious disease, explains Kamran Kadkhoda, PhD, with the Laboratory Medicine Department at Cleveland Clinic.

In herd immunity, an individual might not be fully protected from the coronavirus or other illness, but the overall population immunity is high enough to protect most of the population, he says, It would very much depend on the duration of immunity either obtained through natural infection or vaccination.

Theres so much talk about herd immunity these days because people are tired of COVID and looking for a way out, Kadkhoda added, but, most people dont quite get the concept because of a lack of public education and lots of misinformation.

So, we asked Kadkhoda and other experts to get into the details about herd immunity, its relationship to a potential COVID-19 vaccine and more.

Herd immunity is the idea that the infection can no longer spread within the population once a certain percentage of the population is immune to infection, says James Wantuck, chief medical officer of telehealth company PlushCare. The thinking is that even though not 100% of the population is immune, there arent enough people left to spread it for the infection to sustain itself, meaning it simply disappears from the population over time, he adds. This is how we have eradicated some infections, like smallpox, through a mass vaccination program.

The idea is popular because it offers a light at the end of the tunnel, Wantuck says, The important point here is that herd immunity requires the vast majority of the population to be immuneand, this means that people either had the infection and survived or that they received a vaccine.

Herd immunity conversations too often center on letting enough people get infected and not waiting for a safe, effective vaccine. This view can be harmful, though, says Kim Kilby, a family and preventative medicine physician and regional medical director of MVP Health Care, It misses the problem that with millions of people infected, we strain our medical resources and create potential rationing, while guaranteeing that many more people will die from the disease.

Scientists are learning new things about the coronavirus every day. And, still too little is known about immunity and COVID-19, Kilby says, We do not know if natural infection results in long-term or even short-term protection from future illness; we do not know if a person who recovers from COVID-19 can get infected again later and spread the virus without showing illness.

Most studies on coronavirus and immunity have been small and not produced consistent results. Though, there are reports of people getting re-infected after having coronavirus.

Related: Does a Negative COVID-19 Test Mean You Can Hang Out with Family and Friends?

Generally, scientists believe the virus that causes COVID-19 acts like many other viruses that have been studied extensively, Wantuck explains. So, once infected, your body produces antibodies that fight off the virus and prevent re-infection. The antibodies wane as the virus leaves your body, but the immune system remembers and could produce a defense if youre exposed to the virus again. But, no one is sure how long immunity could last.

Recently, Pfizer and BioNTech applied for emergency authorization from the FDA for their coronavirus vaccine. And, other drug companies have reported that their vaccines have efficacy rates above 90%.

Safe, effective vaccines are a must to achieve herd immunity. Theyll help the immune system generate a protective response to coronavirus, without serious disease consequences, like long-term disability or death, Kilby says.

Related: Everything You Need to Know About a Possible COVID-19 Vaccine

But a vaccine alone isnt enough. People need to actually get vaccinated when one is available. When people choose not to get vaccinated for a serious infectious disease, they put themselves, their familiesespecially those most vulnerable like children and grandparentsand their communities at risk, which puts an additional strain on medical resources, Kilby adds.

Depending on how effective the vaccine is and how long it protects you, there are different thresholds of the population that need to be immunized, Wantuck says, Mass immunization and diligent public health work in contact tracing and outbreak containment would be needed to make herd immunity a possibility.

It depends on how you look at it, Kadkhoda says. Herd immunity is based on the idea that once a certain percentage of the population is immune to infection, it can no longer spread. So, does that mean purposefully infecting people could achieve herd immunity? Most experts agree: thats a bad idea.

Creating herd immunity through natural infection is very dangerous, as it risks the health and well-being of individuals, communities, and puts a dangerous strain on our medical resources, Kilby explains. Frontline health care workers are already facing burnout and fatigue from the effects of the virus.

Millions of people could die and others would unnecessarily suffer from the virus were trying to protect against, Wantuck adds, and most of herd immunitys biggest supporters are misinformed or misguided about the concept.

Related: How Long is Coronavirus Contagious?

A recent article published in the Journal of the American Medical Association and co-authored by Dr. Anthony Fauci said low-tech interventions, like wearing masks, social distancing, hand hygiene, limiting crowds and gatherings, testing and contract tracing are still the most effective ways of fighting COVID-19.

It could take a while for a vaccine to be rolled out. When it does, it should be viewed as an additional measure for stopping the spread of the coronavirus, not a replacement for these low-tech tools, Kilby explains.

When safe and effective vaccines become available, people should embrace their use and get vaccinated as soon as possible, she says.

Get good vibes and health tips delivered right to your inbox!

For now, the best approach is to worry less about herd immunity and focus more on the advice that health officials keep emphasizing, Kadkhoda says. Social distancing, mask-wearing, and frequent hand washing are common sense and tried and true scientific ways of protecting us from germs, COVID, among others at least until we have a vaccine that works effectively and durably, he explains.

Next, read about the risks of hanging out indoors without wearing a mask.

Read the original here:
What is Herd Immunity? Can It End the Coronavirus Pandemic? - Parade

Dr. Flynn joined KDA as the Deputy State Veterinarian earlier this year.

Dr. Alex Hagan, a veterinarian in Shelbyville, has been approved by the SBOA to serve as Deputy State Veterinarian, taking Flynns vacated post.

Todays announcement is the result of the most transparent and thorough hiring process the State Board of Agriculture has ever undertaken, said Agriculture Commissioner Dr. Ryan Quarles, who serves as SBOA chairman. With Dr. Flynns regulatory animal health background and Dr. Hagans on-the-farm experience, we have a top-notch team to lead our Office of State Veterinarian.

The State Veterinarian and Deputy State Veterinarian are the chief executive officers of the State Board of Agriculture and lead the KDAs Office of State Veterinarian in its statutory and regulatory activities to prevent, control, and eradicate communicable diseases in the agricultural animal health sector.

A search committee approved by the board recommended Drs. Flynn and Hagan to the State Board of Agriculture. Dr. Flynn replaces Dr. Robert Stout, who announced his intention to retire from the department in December of 2020. Prior to joining the KDA as the Homeland Security Coordinator in 2003, Dr. Stout had served as an equine and large animal veterinarian since 1973. He was appointed Kentucky State Veterinarian by the SBOA in February 2004.

Originally posted here:
Dr. Katie Flynn promoted to Kentucky State Vet position - ABC 36 News - WTVQ

She's living our ancestor's wildest dreams!

Meet Dr. Ashley Roxanne Peterson, the youngest Black female to graduate as an osteopathic physician in America,The Bay State Bannerreports.

Peterson began her studies at the Philadelphia College of Osteopathic Medicine at the age of 19, inspired by Dr. Andrew Taylor Still, the American School of Osteopathy founder. Still was critical to coining the name in 1892 and growing the practice during a time when osteopathic medicine was thought to be a farce, but he was also an abolitionist who allowed both women and Black students to partake in his classes during the time.

Osteopathic medicine looks at the body as one interconnected system, focusing more on prevention and external factors impacting one's health. Peterson felt like this branch of treatment was more in line with her beliefs, choosing to pursue it after learning more about her family history.

"One of the biggest things you can do for your health is to take accountability, by doing some preventative things, such as exercise, lowering your stress levels, taking your medication, vaccines and having screenings like colonoscopies," Peterson said.

During her studies, Peterson discovered that her "ancestors had been unwilling participants in the infamous Tuskegee Study." The 40-year study conducted in 1932 by the United States Public Health Service and Tuskegee University in Alabama involved knowingly infecting 600 Black men with syphilis without their consent to observe the natural history of the disease.

"I always want to make sure people know that my history and legacy is rooted in the poor and oftentimes hurtful history of American slaves. Sometimes, people are ashamed to say their ancestors were slaves. Quite frankly, I'm not ashamed. My ancestors worked so I can have this dream, and I am their wildest dream," Peterson said.

Peterson graduated at age 26, making history as the youngest Black female osteopathic physician in the nation. Only 5% of practicing physicians in the U.S. identify as Black or African American. Peterson hopes that she can inspire more Black students and young girls to follow in her footsteps.

"I've had so many people reach out to me, especially young Black women. There was actually a little girl who, this year, was me for Black History Month. That just made me cry because I guess my story is really inspirational to people. I want to see someone else be the youngest Black osteopathic doctor in the country when they graduate. I want to see someone else break records, be they a young black woman or man or whichever race," said Peterson.

Congratulations, Dr. Peterson!

Photo Courtesy ofVoyageATL

View original post here:
Meet Dr. Ashley Roxanne Peterson, The Youngest Black Woman To Graduate As An Osteopathic Physician In America - Because of Them We Can

SINGAPOREMedia OutReach24 November 2020 In the midst of a global pandemic and economic crisis, MDRT has made strategic moves to ensure financial professionals and their clients are well supported. The association announced its Productivity Action Plan, developed to help financial professionals qualify for membership in 2021, and equip them with proven strategies to drive their businesses and clients towards next-level success in the current climate and beyond.

A relief package for advisors

The MDRT Productivity Action Plan acknowledges the challenging business conditions financial professionals have faced in 2020. To provide its current and aspiring members with more opportunities to join, MDRT announced it has no plans to increase dues in 2021, and waived 2021 production requirements for 2019 and 2020 members, allowing those members to reapply for membership without submitting their production requirements. Considering the economic impacts on the industry, MDRT has also adjusted the production requirements for prior-to-2019 members and new members.

An e-Hub for career progression

Though the pandemic has changed the way many financial professionals do business, MDRT is focused on providing them with the innovative ideas they need to continue succeeding. As part of the Productivity Action Plan, the association developed the MDRT Focus on Resources hub. Available to both members and non-members, the site is updated regularly with timely, top-tier content from industry professionals around the globe, built to help advisors navigate current challenges so they can continue to grow their business, protect their clients and guide both towards a successful future. From how to host productive virtual meetings to managing client emotions, advisors can find the proven strategies they need to adapt, innovate and persevere. MDRT members have exclusive access to even more top-tier ideas via MDRT Resource Zone, Round the Table Magazine, MDRT podcast and more.

My MDRT membership is a big part of what got me to where I am today. Its the innovative ideas and supportive global community that have helped me propel my business to greater levels of success year after year, said Ian Green Dip PFS, 95th MDRT President. MDRT Singapore currently has more than 2,000 members. With this plan, we foresee welcoming more advisors to our network and aim to ensure that advisors can become or stay members, to continue accessing the insightful strategies from leaders of our profession around the world, and most importantly guide their clients towards greater financial security and success.

An online mentorship program for aspiring members

MDRT continues to push boundaries and innovate in ways that help financial professionals at all stages of their career succeed. Future-focused financial advisors who do not yet qualify for MDRT in 2021 can join the MDRT Academy to receive real-time insights and personalized coaching that fast-tracks them to premier status. Newly launched and open for applications, the MDRT Academy is a new kind of association with gold-standard content that is either MDRT-original or MDRT-approved available anytime, anywhere.

As a young financial advisor aspiring to get to the next level, the MDRT Academy app was the perfect tool, said Brandon Heckert, former MDRT Academy member and current MDRT member. It allowed me to keep track of my goals and obtain the resources I needed to conduct my practice in a tech-focused world.

The Productivity Action Plan is just one of the forward-thinking ways that MDRT has leveraged to support its members and help them thrive in 2020 and beyond. In August, the association adapted its quintessential MDRT Annual Meeting and recently established 2019 Global Conference into a singular Virtual Event. Members collaborated on fresh ideas for virtual practice management, social media marketing and more. On-Demand content was released the following weeks, diving deeper into dynamic strategies for ways to avoid burn out and help clients readjust their portfolios to thrive amid the current crisis.

2021 MDRT membership application is open from now through March 1, 2021. To learn more about the MDRT Productivity Action Plan and becoming an MDRT member, visit mdrt.org.

Founded in 1927, Million Dollar Round Table (MDRT), The Premier Association of Financial Professionals, is a global, independent association of more than 65,000 of the worlds leading life insurance and financial services professionals from more than 500 companies in 70 nations and territories. MDRT members demonstrate exceptional professional knowledge, strict ethical conduct and outstanding client service. MDRT membership is recognized internationally as the standard of excellence in the life insurance and financial services business. For more information, please visit http://www.mdrt.org and follow them on Twitter [View Image]@MDRtweet.

Follow this link:
ViacomCBS CEO Bob Bakish to Participate in the Virtual UBS Conference - Global Banking And Finance Review